Proliferation indices of phosphohistone H3 and Ki67: Strong prognostic markers in a consecutive cohort with stage I/II melanoma

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 404-413

  Nielsen, Patricia S ^a   Riber Hansen, Rikke ^a   Jensen, Trine O ^a   Schmidt, Henrik ^a   Steiniche, Torben ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

computer assisted image analysis; immunohistochemical double staining; Ki67; melanoma; phosphohistone H3; prognosis

Indexed keywords

EOSIN; HEMATOXYLIN; HISTONE H3; KI 67 ANTIGEN; MELAN A; PHOSPHOHISTONE H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER;

ADULT; AGED; CELL PROLIFERATION; COLORING AGENTS; DENMARK; DISEASE-FREE SURVIVAL; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HISTONES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAFFIN EMBEDDING; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; STAINING AND LABELING; TIME FACTORS; YOUNG ADULT;

EID: 84875212173     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.188     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304.
3. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-681.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
5. Piris A, Mihm MC, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011;38: 394-400.
6. Weyers W. The magic of numbers: malignant melanoma between science and pseudoscience. Am J Dermatopathol 2011;33:371-378.
7. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010;32:650-654.
8. Vereecken P, Laporte M, Heenen M. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review. J Cutan Pathol 2007;34:139-145.
9. Schimming TT, Grabellus F, Roner M, et al. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol 2012;34:266-269.
10. Scholzen T, Gerdes J. The ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182: 311-322.
11. de Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-1513.
12. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-2025.
13. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-360.
14. Tapia C, Kutzner H, Mentzel T, et al. Two mitosisspecific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006;30:83-89.
15. Ikenberg K, Pfaltz M, Rakozy C, et al. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. J Cutan Pathol 2012; 39:324-330.
16. Skaland I, Janssen EA, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007;20:1307-1315.
17. Kim YJ, Ketter R, Steudel WI, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007;128:118-125.
18. Lende TH, Janssen EA, Gudlaugsson E, et al. In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol 2011;29:852-858.
19. Ladstein RG, Bachmann IM, Straume O, et al. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol 2012;132:1247-1252.
20. Nielsen PS, Riber-Hansen R, Steiniche T. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 2011; 33:361-370.
21. Puri PK, Valdes CL, Burchette JL, et al. Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. J Cutan Pathol 2010;37:1010-1012.
22. Nielsen PS, Riber-Hansen R, Raundahl J, et al. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. Arch Pathol Lab Med 2012;136:627-634.
23. Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009;27:3330-3337.
24. Frishberg DP. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009;133:1560-1567.
25. Altman DG. Practical Statistics for Medical Research. Chapman & Hall: London; 1991, pp 367-395.
26. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49: 1373-1379.
27. Kleinbaum DG. Survival analysis: a self-learning text. Springer: New York; 1996, pp 135-144.
28. Hosmer DW. Applied survival analysis, regression modeling of time-to-event data, 2nd ed. John Wiley & Sons, Inc.: Hoboken; 2008, pp 136.
29. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 2010;10:140.
30. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-1853.
31. Aoki Y, Moore GE. Comparative study of mitotic stages of cells derived from human peripheral blood. Exp Cell Res 1970;59:259-266.
32. Pierard GE. Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol 2012;2012:828146.
33. Henrique R, Azevedo R, Bento MJ, et al. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000;43:991-1000.
34. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol 2011;89: e155-e160.